How does illumina sequencing work

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Illumina sequencing, also known as sequencing by synthesis (SBS), is a next-generation sequencing technology that determines DNA sequences by detecting fluorescently labeled nucleotides as they are incorporated into growing DNA strands. It was first introduced commercially in 2006 with the Genome Analyzer, enabling massively parallel sequencing of millions of DNA fragments simultaneously. The process involves bridge amplification on a flow cell to create clusters of identical DNA fragments, followed by cyclic reversible termination where fluorescently labeled nucleotides are added one at a time and imaged. This method can generate up to 6 terabases of data per run on high-throughput systems like the NovaSeq 6000, with read lengths typically ranging from 50 to 300 base pairs.

Key Facts

Illumina sequencing was first commercially introduced in 2006 with the Genome Analyzer system
The technology can generate up to 6 terabases of data per run on high-throughput systems like NovaSeq 6000
Read lengths typically range from 50 to 300 base pairs depending on the platform and chemistry
The process uses sequencing by synthesis (SBS) with fluorescently labeled nucleotides
Bridge amplification creates clusters of approximately 1,000 identical DNA fragments on the flow cell surface

Overview

Illumina sequencing, developed by the company Illumina, Inc., represents a revolutionary approach to DNA sequencing that has transformed genomic research since its commercial introduction in 2006. Building upon earlier sequencing methods like Sanger sequencing, Illumina's technology enabled massively parallel sequencing at unprecedented scale and reduced cost. The development was based on sequencing by synthesis (SBS) technology, which was initially described in scientific literature in the late 1990s and refined through the 2000s. The first commercial system, the Genome Analyzer, could sequence 1 gigabase per run, representing a 100-fold increase over previous technologies. This breakthrough coincided with the completion of the Human Genome Project in 2003, which had cost approximately $2.7 billion using earlier methods. By dramatically reducing sequencing costs and increasing throughput, Illumina sequencing made large-scale genomic studies feasible and helped launch the era of personalized medicine.

How It Works

Illumina sequencing operates through a multi-step process beginning with library preparation, where DNA is fragmented and adapters are attached to both ends. These fragments are then loaded onto a flow cell where they bind to complementary oligonucleotides. Through bridge amplification, each fragment is amplified into a cluster of approximately 1,000 identical copies, creating millions of clusters across the flow cell surface. The actual sequencing occurs through cyclic reversible termination: fluorescently labeled nucleotides with reversible terminators are added one at a time by DNA polymerase. After each nucleotide incorporation, the flow cell is imaged to detect the fluorescent signal from each cluster, identifying which base was added. The terminator is then removed, allowing the next cycle to begin. This process repeats for the desired read length, typically 50-300 cycles. Finally, the sequenced reads are aligned to a reference genome or assembled de novo using bioinformatics tools to reconstruct the original DNA sequence.

Why It Matters

Illumina sequencing has revolutionized genomics by making DNA sequencing faster, cheaper, and more accessible. The technology has enabled the $1,000 genome milestone, dramatically reducing the cost of sequencing a human genome from millions to thousands of dollars. This has transformed biomedical research, allowing large-scale studies of genetic variation in populations, cancer genomics, and rare disease diagnosis. In clinical settings, Illumina sequencing enables non-invasive prenatal testing, cancer biomarker detection, and infectious disease surveillance. The COVID-19 pandemic highlighted its importance for tracking viral evolution through genomic surveillance. Beyond healthcare, applications extend to agriculture for crop improvement, forensics for DNA profiling, and conservation biology for biodiversity monitoring. By democratizing access to genomic information, Illumina sequencing continues to drive discoveries across multiple scientific disciplines.